Related references
Note: Only part of the references are listed.Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa
Maria Teresa Alvarez Roman et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2021)
Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy
Johannes Oldenburg et al.
CURRENT MEDICAL RESEARCH AND OPINION (2020)
Hemophilia therapy: the future has begun
Pier Mannuccio Mannucci
HAEMATOLOGICA (2020)
Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B
Maria Elisa Mancuso et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis
Cedric Hermans et al.
ADVANCES IN THERAPY (2020)
Long-Term Safety and Efficacy of Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Previously Treated Pediatric Patients with Hemophilia B: Results from a Phase 3b Extension Study
Gili Kenet et al.
THROMBOSIS AND HAEMOSTASIS (2020)
High adherence to prophylaxis regimens in haemophilia B patients receiving rIX-FP: Evidence from clinical trials and real-world practice
Maria Elisa Mancuso et al.
HAEMOPHILIA (2020)
Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa, rFIX-FP) in Spain
Manuel Rodriguez Lopez et al.
BMJ CASE REPORTS (2020)
Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B
Joan C. Gill et al.
HAEMOPHILIA (2019)
Health-related quality of life in paediatric haemophilia B patients treated with rIX-FP
Sylvia von Mackensen et al.
HAEMOPHILIA (2019)
The benefits of prophylaxis in patients with hemophilia B
Giancarlo Castaman
EXPERT REVIEW OF HEMATOLOGY (2018)
Coagulation Factor IX (Recombinant), Albumin Fusion Protein (Albutrepenonacog Alfa; Idelvion®): A Review of Its Use in Haemophilia B
Katherine A. Lyseng-Williamson
DRUGS (2017)
Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates
Maria Elisa Mancuso et al.
JOURNAL OF CLINICAL MEDICINE (2017)
Current management of hemophilia B: recommendations, complications and emerging issues
Massimo Franchini
EXPERT REVIEW OF HEMATOLOGY (2014)
Barriers and perceived limitations to early treatment of hemophilia
Kapil Saxena
JOURNAL OF BLOOD MEDICINE (2013)
Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients
Elena Santagostino et al.
BLOOD (2012)
A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)
A. Gringeri et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
Back to the future: a recent history of haemophilia treatment
P. M. Mannucci
HAEMOPHILIA (2008)
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Marilyn J. Manco-Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Share Paper
